Literature DB >> 15515405

Expression of 5-HT3A receptors in cells of the immune system.

B L Fiebich1, R S Akundi, M Seidel, V Geyer, U Haus, W Müller, T Stratz, E Candelario-Jalil.   

Abstract

There is evidence from both human and animal research that 5-hydroxytryptamine3 (5-HT3) receptor antagonists, particularly tropisetron, exert analgesic and antiinflammatory effects. However, the underlying mechanisms of these effects including the expression of 5-HT3 receptors in cells of the immune system have not yet been investigated in detail. Therefore, we investigated the expression of the 5-HT3A receptor in primary human monocytes, chondrocytes, T-cells, dendritic cells, and synovial tissue. We found that 5-HT3A receptors are expressed in monocytes, chondrocytes, T-cells, and synovial tissue but not in dendritic cells. Our data show that 5-HT3A receptors are widely expressed in cells of the immune system and that they might play an important role in inflammatory events and in the observed antiphlogistic effects of 5-HT3 receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15515405

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


  28 in total

1.  Serotonin receptor diversity in the human colon: Expression of serotonin type 3 receptor subunits 5-HT3C, 5-HT3D, and 5-HT3E.

Authors:  Johannes Kapeller; Dorothee Möller; Felix Lasitschka; Frank Autschbach; Ruud Hovius; Gudrun Rappold; Michael Brüss; Michael D Gershon; Beate Niesler
Journal:  J Comp Neurol       Date:  2011-02-15       Impact factor: 3.215

2.  New roles of serotonin and tachykinins in intestinal mucositis?

Authors:  Brid Callaghan; John B Furness
Journal:  Dig Dis Sci       Date:  2013-12       Impact factor: 3.199

3.  Involvement of 5HT3 Receptors in Anti-Inflammatory Effects of Tropisetron on Experimental TNBS-Induced Colitis in Rat.

Authors:  Azadeh Motavallian; Mohsen Minaiyan; Mohammad Rabbani; Sasan Andalib; Parvin Mahzouni
Journal:  Bioimpacts       Date:  2013-06-18

4.  Enhancement of intestinal inflammation in mice lacking interleukin 10 by deletion of the serotonin reuptake transporter.

Authors:  S Haub; Y Ritze; I Bergheim; O Pabst; M D Gershon; S C Bischoff
Journal:  Neurogastroenterol Motil       Date:  2010-03-08       Impact factor: 3.598

Review 5.  The 5-HT3 receptor as a therapeutic target.

Authors:  Andrew J Thompson; Sarah C R Lummis
Journal:  Expert Opin Ther Targets       Date:  2007-04       Impact factor: 6.902

Review 6.  From Chemotherapy-Induced Emesis to Neuroprotection: Therapeutic Opportunities for 5-HT3 Receptor Antagonists.

Authors:  Gohar Fakhfouri; Kazem Mousavizadeh; Sharam Ejtemaei Mehr; Ahmad Reza Dehpour; Mohammad Reza Zirak; Jean-Eric Ghia; Reza Rahimian
Journal:  Mol Neurobiol       Date:  2014-11-07       Impact factor: 5.590

7.  Therapeutic action of 5-HT3 receptor antagonists targeting peritoneal macrophages in post-operative ileus.

Authors:  Toko Maehara; Kenjiro Matsumoto; Kazuhide Horiguchi; Makoto Kondo; Satoshi Iino; Shunji Horie; Takahisa Murata; Hirokazu Tsubone; Shoichi Shimada; Hiroshi Ozaki; Masatoshi Hori
Journal:  Br J Pharmacol       Date:  2015-01-13       Impact factor: 8.739

8.  5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells.

Authors:  M Yasuda; S Kato; N Yamanaka; M Iimori; K Matsumoto; D Utsumi; Y Kitahara; K Amagase; S Horie; K Takeuchi
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

9.  5-Chloroindole: a potent allosteric modulator of the 5-HT₃ receptor.

Authors:  Amy S Newman; Nikolaos Batis; Gillian Grafton; Francesca Caputo; Catherine A Brady; Jeremy J Lambert; John A Peters; John Gordon; Keith L Brain; Andrew D Powell; Nicholas M Barnes
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

10.  The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors.

Authors:  Akash Pandhare; Aneesh Satya Pappu; Henrik Wilms; Michael Paul Blanton; Michaela Jansen
Journal:  Neuropharmacology       Date:  2016-09-24       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.